A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
Latest Information Update: 21 Jan 2026
At a glance
- Drugs CMTX 101 (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions
- Sponsors Clarametyx Biosciences
Most Recent Events
- 09 Jan 2026 Results presented in the Clarametyx Biosciences Media Release.
- 09 Jan 2026 According to Clarametyx Biosciences media release, Comprehensive data analyses from this study will be presented at an upcoming scientific conference.
- 21 Nov 2025 Status changed from active, no longer recruiting to completed.